l
The patient was found to have a rising WBC count despite taking desatinib for over 2 months. He had previously been documented to have recurrent disease after successfully achieving cytogenetic remission on imatinib.
Relapsed accelerated CML – T315I mutation - 1.
Author:
Peter Maslak
Category: Myeloid Neoplasms and acute leukemia (WHO 2016) > Myeloproliferative Neoplasms (MPN) > Chronic Myelogenous Leukemia (CML), BCR-ABL1+
Published Date: 03/01/2010
Category: Myeloid Neoplasms and acute leukemia (WHO 2016) > Myeloproliferative Neoplasms (MPN) > Chronic Myelogenous Leukemia (CML), BCR-ABL1+
Published Date: 03/01/2010
The patient was found to have a rising WBC count despite taking desatinib for over 2 months. He had previously been documented to have recurrent disease after successfully achieving cytogenetic remission on imatinib.
